⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Methylnaltrexone

متیل‌نالترکسون

⚠ Unverified

🍽️ Alimentary Tract And MetabolismPeripherally acting opioid antagonist (PAMORA)

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Dangerous / avoid 👶 Children:Use with caution 👴 Older adults:Use with caution 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA208271 ATC A06AH01

Market / country: 🇺🇸 USA

Relistor (US)

🧮 Dose calculator

Disease / regimen

Opioid-induced constipation · Regimen source: FDA Relistor · 2.2

• Stop maintenance laxatives before starting. Stay near a toilet. Stop when the opioid is stopped. FDA Relistor · 2.1

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ Known or suspected GI obstruction and risk of recurrent obstruction. FDA Relistor · 4

Warnings

• GI perforation; severe diarrhoea or abdominal pain; opioid withdrawal. FDA Relistor · 5

Renal adjustment

• eGFR < 60: CrCl <60: tablets 150 mg; injection 6 mg (non-cancer pain); advanced illness half the table dose. FDA Relistor · 2.4

Formulations

150 mg tablet — tablet 🇺🇸 USA FDA Relistor · 3
12 mg/0.6 mL vial or syringe (8 mg/0.4 mL syringe) — injection 🇺🇸 USA FDA Relistor · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Relistor · 8.1
“Risk Summary The limited available data with RELISTOR in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriages.”
🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Relistor · 8.2
“Because of the potential for serious adverse reactions, including opioid withdrawal, in breastfed infants, advise women that breastfeeding is not recommended during treatment with RELISTOR.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Relistor · 8.4
“Safety and effectiveness of RELISTOR tablets and injection have not been established in pediatric patients.”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Relistor · 8.5
“Monitor elderly patients for adverse reactions.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA208271
DailyMed (FDA label)FDA Relistor
MedlinePlus (NIH)Methylnaltrexone Methylnaltrexone Injection
WHO ATC/DDDA06AH01
Darooyab (Iran)Methylnaltrexone

🇮🇷 Not found in Iran list Darooyab · G-5289/Methylnaltrexone

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Relistor · 3 FDA Relistor · 2.2 FDA Relistor · 2.1 FDA Relistor · 2.3, Table 1 FDA Relistor · 4 FDA Relistor · 5 FDA Relistor · 2.4 FDA Relistor · 8.1 FDA Relistor · 8.2 FDA Relistor · 8.4 FDA Relistor · 8.5 FDA Relistor · SPL approval / marketing category
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-5289/Methylnaltrexone
Clinical review⚠ Unverified